ADARx Pharmaceuticals, Inc.
ADARx Pharmaceuticals, Inc. is a biotechnology company headquartered in San Diego, USA. The company is currently in the late-clinical-stage of development and focuses on creating next-generation small interfering RNA (siRNA) therapeutics. These medical treatments are designed for diseases that present significant…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
1D
-0.3%
1W
-0.7%
1M
–
6M
–
YTD
–
1Y
–
2Y
–
5Y
–
10Y
–
FREE FLOAT
16.9%
FLOAT SHARES
18,080,054
AVG. DAILY VOLUME (30D)
909,855
Chimovits Erez
ORBIMED ADVISORS LLC
ORBIMED ADVISORS LLC
ORBIMED ADVISORS LLC
ORBIMED ADVISORS LLC
ADARx Pharmaceuticals, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Zhen Li, the company employs around 100 people.
The IPO was on 25/09/2026; the stock trades on NASDAQ under the ticker ADRX.
No, ADARx Pharmaceuticals currently does not pay a dividend.
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
Clicking "Analyze stock" lets five strategies assess ADARx Pharmaceuticals against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.